Portal de Periódicos da CAPES

Predictive Biomarkers for Immunotherapy in the Treatment of Advanced Urothelial Carcinoma: Where We Stand and Where We Go

2019; Future Medicine; Volume: 15; Issue: 19 Linguagem: Inglês

10.2217/fon-2019-0217

1744-8301

Thomas Gevaert, Alessia Cimadamore, Markus Eckstein, Marina Scarpelli, Antonio López-Beltrán, Liang Cheng, Rodolfo Montironi,

Cancer Immunotherapy and Biomarkers

Future OncologyVol. 15, No. 19 EditorialPredictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we goThomas Gevaert‡, Alessia Cimadamore‡, Markus Eckstein, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng & Rodolfo MontironiThomas Gevaert‡Department of Urology, UZ Leuven, Leuven, BelgiumOrgan Systems, Department of Development and Regeneration, KU Leuven, Leuven, BelgiumDepartment of Pathology, AZ Klina, Brasschaat, Belgium, Alessia Cimadamore‡Section of Pathological Anatomy, Marche Polytechnic University, School of Medicine, United Hospitals, Ancona, Italy, Markus EcksteinDepartment of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, Marina ScarpelliSection of Pathological Anatomy, Marche Polytechnic University, School of Medicine, United Hospitals, Ancona, Italy, Antonio Lopez-BeltranDepartment of Surgery, Cordoba University Medical School, Cordoba, Spain, Liang ChengDepartment of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA & Rodolfo Montironi*Author for correspondence: E-mail Address: r.montironi@univpm.itSection of Pathological Anatomy, Marche Polytechnic University, School of Medicine, United Hospitals, Ancona, ItalyPublished Online:19 Jun 2019https://doi.org/10.2217/fon-2019-0217AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: atezolizumabbasal-typegenitourinary tumorsimmunotherapyluminal-typelymphocytesmicrobiomePD-L1urothelial carcinomaReferences1. Mehta K, Patel K, Parikh RA. Immunotherapy in genitourinary malignancies. J. Hematol. Oncol. 10, 95 (2017).Crossref, Medline, Google Scholar2. Gevaert T, Montironi R, Lopez-Beltran A et al. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. Semin. Cancer Biol. 52(Pt 2), 216–227 (2018).Crossref, Medline, CAS, Google Scholar3. American Association for Cancer Research. Three drugs approved for urothelial carcinoma by FDA | Cancer Discovery. (2017) http://cancerdiscovery.aacrjournals.org/content/7/7/659Google Scholar4. Kourie HR, Klastersky J. Immune checkpoint inhibitors side effects and management. Immunotherapy 8, 799–807 (2016).Link, CAS, Google Scholar5. Goldstein DA. Financial toxicity in cancer care – edging toward solutions. Cancer 123, 1301–1302 (2017).Crossref, Medline, Google Scholar6. US FDA. FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients (2018). www.fda.gov/drugs/informationondrugs/approveddrugs/ucm612484.htmGoogle Scholar7. Necchi A, Anichini A, Raggi D et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, Phase II study. J. Clin. Oncol. 36, 3353–3360 (2018).Crossref, Medline, CAS, Google Scholar8. Rijnders M, van der Veldt AAM, Zuiverloon TCM et al. PD-L1 antibody comparison in urothelial carcinoma. Eur. Urol. 75(3), 538–540 (2019).Crossref, Medline, CAS, Google Scholar9. Eckstein M, Erbenb P, Kriegmair MC et al. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur. J. Cancer 106, 234–243 (2019).Crossref, Medline, CAS, Google Scholar10. Gevaert T, Eckstein M, Montironi R et al. PD-L1 antibody comparison in urothelial carcinoma. Eur. Urol. doi:10.1016/j.eururo.2019.01.038 (2019) (In Press).Medline, Google Scholar11. Lerner SP, McConkey DJ, Hoadley KA et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer 2(1), 37–47 (2016).Crossref, Medline, Google Scholar12. Robertson AG, Kim J, Al-Ahmadie H et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171(3), 540–556.e25 (2017).Crossref, Medline, CAS, Google Scholar13. Kim J, Kwiatkowski D, McConkey DJ et al. The Cancer Genome Atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur. Urol. 75(6), 961–964 (2019).Crossref, Medline, CAS, Google Scholar14. Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, Phase II trial. Lancet Lond. Engl. 387, 1909–1920 (2016).Crossref, Medline, CAS, Google Scholar15. Teo MY, Seier K, Ostrovnaya I et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J. Clin. Oncol. 36, 1685–1694 (2018).Crossref, Medline, CAS, Google Scholar16. Mariathasan S, Turley SJ, Nickles D et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).Crossref, Medline, CAS, Google Scholar17. Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP. Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur. Urol. 75(3), 423–432 (2019).Crossref, Medline, CAS, Google Scholar18. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492), 315–322 (2014).Crossref, Medline, Google Scholar19. Balar AV, Galsky MD, Rosenberg JE et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, Phase II trial. Lancet 389, 67–76 (2017).Crossref, Medline, CAS, Google Scholar20. Massari F, Mollica V, Di Nunno V et al. The human microbiota and prostate cancer: friend or foe? Cancers (Basel) 11(4), pii:E459 (2019).Crossref, Google Scholar21. Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur. J. Immunol. 45, 17–31 (2015).Crossref, Medline, CAS, Google Scholar22. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369–2379 (2016).Crossref, Medline, CAS, Google Scholar23. Reid G. Microbes in food to treat and prevent disease. Exp. Rev. Precision Med. Drug Develop. 3(2), 79–81 (2018).Crossref, Google Scholar24. Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA. The application of ecological theory toward an understanding of the human microbiome. Science 336, 1255–1262 (2012).Crossref, Medline, CAS, Google Scholar25. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 13, 260–270 (2012).Crossref, Medline, CAS, Google Scholar26. Schwabe RF, Jobin C. The microbiome and cancer. Nat. Rev. Cancer 13, 800–812 (2013).Crossref, Medline, CAS, Google Scholar27. Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat. Rev. Cancer 17, 271–285 (2017).Crossref, Medline, CAS, Google Scholar28. Brandi G, Dabard J, Raibaud P et al. Intestinal microflora and digestive toxicity of irinotecan in mice. Clin. Cancer Res. 12(4), 1299–1307 (2006).Crossref, Medline, CAS, Google Scholar29. Routy B, Le Chatelier E, Derosa L et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371), 91–97 (2018).Crossref, Medline, CAS, Google Scholar30. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 359(6382), 1366–1370 (2018).Crossref, Medline, CAS, Google Scholar31. Mazzucchelli R, Gasparrini S, Galosi AB et al. Immunotargeting and personalized therapies in genitourinary cancers. Future Oncol. 12(16), 1853–1856 (2016).Link, CAS, Google Scholar32. Lovitch SB, Rodig SJ. The role of surgical pathology in guiding cancer immunotherapy. Annu. Rev. Pathol. 11, 313–341 (2016).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByImmune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review)24 October 2022 | Creative surgery and oncology, Vol. 12, No. 3Tumors of the Urinary BladderClinical therapies and nano drug delivery systems for urinary bladder cancerPharmacology & Therapeutics, Vol. 226An update on immunotherapy in uro-oncology3 May 2021 | Expert Review of Precision Medicine and Drug Development, Vol. 6, No. 4Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma16 July 2021 | Biology, Vol. 10, No. 7Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients12 May 2021 | Cancers, Vol. 13, No. 10PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future PerspectivesCurrent Drug Targets, Vol. 22, No. 2Stage T1 bladder cancer: diagnostic criteria and pitfallsPathology, Vol. 53, No. 1Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer3 January 2021 | Cancers, Vol. 13, No. 1Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer19 June 2020 | Cells, Vol. 9, No. 6 Vol. 15, No. 19 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 283 times History Received 15 April 2019 Accepted 2 May 2019 Published online 19 June 2019 Published in print July 2019 Information© 2019 Future Medicine LtdKeywordsatezolizumabbasal-typegenitourinary tumorsimmunotherapyluminal-typelymphocytesmicrobiomePD-L1urothelial carcinomaFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download